Drug Profile
Research programme: CNS biologics and imaging agents - ImaginAb/Lundbeck
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator ImaginAb; Lundbeck A/S
- Developer ImaginAb Inc; Lundbeck A/S
- Class Antibody diagnostics; Imaging agents
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neurodegenerative disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Neurodegenerative-disorders in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Neurodegenerative-disorders(Diagnosis) in USA (Parenteral)
- 08 Oct 2012 Early research in Neurodegenerative disorders (diagnosis) in USA (Parenteral)